Moderna is now expecting 2025 research and development costs of about $4.1 billion and selling, general and administrative costs of about $1.1 billion. Cost of sales is expected to come to about $1.2 ...

Moderna MRNA incurred a loss of $2.50 per share in the fourth quarter of 2024, narrower than the Zacks Consensus Estimate of ...

MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...

A bill that would ban the use of mRNA vaccines, including for Covid-19, is on its way to the House floor after passing out of ...

The current health news highlights include Moderna's unexpected losses due to scaling down vaccine production, WHO's call for ...

Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 billion of non-cash charges related to manufacturing resizing ...

WASHINGTON, DC – Two Indian Americans, Yale Law School professor Natasha Sarin and surgical oncologist Dr. Vinod Balachandran ...

In a landmark achievement for both Uganda and the global medical community, the United States Patent and Trademark Office ...

A New Hope? Russia has developed a therapeutic cancer vaccine, which means it won’t prevent cancer but aims to cure it.

That’s thanks to a major philanthropic commitment from Sarasota’s Brian and Sheila Jellison Family Foundation. As the first ...

We recently compiled a list of the 12 Best Healthcare Stocks to Buy According to Analysts. In this article, we are going to take a look at where Moderna, Inc. (NASDAQ:MRNA) stands against the other ...